International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-4
Original Article
Pharmacovigilance Study of Antibiotics in a Tertiary Care Hospital
 ,
 ,
 ,
Published
Aug. 24, 2023
Abstract

Background: Antibioticsare currently the most commonly prescribed drugs in hospitals, worldwide. Detecting ADRs and establishing preventive measures is essential for patient safety.

Methods: A prospective, Cross-sectional, Observational study was conducted at inpatient and outpatient Department of Medicine in tertiary health care centre. 96 patient’s relevant medical history were obtained from ADR forms (CDSCO forms) and patients files from 1 October 2022 to 31 December 2022.

Results: A total of 96ADR forms and patients’ files were collected, analysed and assessed on WHO causality assessment scale. It was observed that male patients 58(60.41%) predominated over females 38 (39.58%) in ADR occurrence. Age wise distribution of the ADRs revealed that the Middle-aged patients were more accounted 41 (42.70 %), followed by geriatric28 (29.16 %), and Adult 23 (23.95 %). ADRs reported with Beta-Lactams were 37(38.54%) followed by Aminoglycosides19 (19.79%), and Quinolones 15(15.62%). GIT 29(30.20%) was the most affected organ system by Adverse Drug Reactions. The most common ADR was Abdominal pain 13(13.54%), Dyspnoea, Diarrhoea, Rashes 08 (8.33%), Vomiting, allergic reactions 6 (6.25%) and Cough. Severity assessment showed that out of 96 ADRs, mild reactions were high followed by moderate and severe reaction.

Conclusion: This study concluded the spontaneous reporting of Adverse Drug Reactions to antibiotics and other drugs, proper documentation and periodic reporting to regional pharmacovigilance centres should be promoted to ensure drug safety.

Recommended Articles
Loading Image...
Volume-4, Issue-4
Citations
2210 Views
266 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved